-
公开(公告)号：US11981747B1
公开(公告)日：2024-05-14
申请号：US18365828
申请日：2023-08-04
发明人： Yukinari Kato , Mika Kaneko , Daisuke Nakayama , Masayuki Kurogi
IPC分类号： C07K16/32
CPC分类号： C07K16/32 , C07K2317/34 , C07K2317/622 , C07K2317/92
摘要： An antibody or antigen-binding fragment thereof is disclosed. The antibody or antigen-binding fragment thereof binds to HER2 expressed on a cancer cell or a fragment of the HER2. A HER2-targeting agent containing any of the antibody or antigen-binding fragment thereof, and a pharmaceutical composition containing the HER2-targeting agent are disclosed.
-
公开(公告)号：US20240010658A1
公开(公告)日：2024-01-11
申请号：US18472970
申请日：2023-09-22
IPC分类号： C07D495/14 , C07D409/14 , C07D417/14 , C07D405/14 , C07D513/04 , C07D495/04 , C07D487/04 , A61P29/00
CPC分类号： C07D495/14 , C07D409/14 , C07D417/14 , C07D405/14 , C07D513/04 , C07D495/04 , C07D487/04 , A61P29/00
摘要： A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
in which all symbols represent the same meaning as the symbols described in the specification.-
公开(公告)号：US20240002532A1
公开(公告)日：2024-01-04
申请号：US18346130
申请日：2023-06-30
发明人： Bahram VALAMEHR , Tom Tong LEE , Martin HOSKING , Susumu YAMAMOTO , Tatsuo MAEDA
IPC分类号： C07K16/32 , C07K14/705 , C07K14/725
CPC分类号： C07K16/32 , C07K14/70521 , C07K14/7051 , C07K2319/03 , C07K2319/02 , C07K2319/33
摘要： Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.
-
公开(公告)号：US20230390303A1
公开(公告)日：2023-12-07
申请号：US18035608
申请日：2021-11-12
发明人： Maki KONDO
IPC分类号： A61K31/555 , A61K31/337 , A61K31/513 , A61K31/7068 , A61K31/4745 , A61K31/519 , A61K31/506 , A61K31/353 , C07K16/28 , A61P35/00
CPC分类号： A61K31/555 , A61K31/337 , A61K31/513 , A61K31/7068 , A61P35/00 , A61K31/519 , A61K31/506 , A61K31/353 , C07K16/2827 , A61K31/4745
摘要： The object of the present invention is to provide an effective method for treating cancer. Provided is a method for treating cancer including a combination of a standard therapy, an EP4 antagonist and an immune checkpoint inhibitor (for example, an anti-PD-1 antibody). The therapeutic method of the present invention is useful for cancer treatment.
-
公开(公告)号：US20230272079A1
公开(公告)日：2023-08-31
申请号：US18167012
申请日：2023-02-09
发明人： Alan J. KORMAN , Mohan SRINIVASAN , Changyu WANG , Mark J. SELBY , Bingliang CHEN , Josephine M. CARDARELLI , Haichun HUANG
IPC分类号： C07K16/28 , A61P7/06 , A61K47/68 , C07K16/18 , A61K39/395 , C07K16/46 , A61K51/10 , A61K39/00
CPC分类号： C07K16/2818 , A61P7/06 , A61K47/6849 , C07K16/18 , A61K39/3955 , C07K16/468 , A61K51/10 , C07K16/28 , A61K39/39558 , A61K39/00 , C07K16/2803 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/52 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/732 , Y02A50/30 , C07K2317/73 , A61K2039/507 , C07K2317/33 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
公开(公告)号：US20230141284A1
公开(公告)日：2023-05-11
申请号：US17916268
申请日：2021-04-09
发明人： Kazuhiko TAKEDA , Ryohei MIYATA , Tomoya KOIKE , Akira KATSUBE
IPC分类号： A61K31/437 , A61K39/395 , A61K31/573 , A61P35/00 , A61K31/635 , A61K31/7068 , A61K31/706 , A61P35/02 , A61P17/00 , A61P1/00 , A61K31/675 , A61K31/4545 , A61K31/444 , A61K31/5377 , A61K31/685
CPC分类号： A61K31/437 , A61K39/3955 , A61K31/573 , A61P35/00 , A61K31/635 , A61K31/7068 , A61K31/706 , A61P35/02 , A61P17/00 , A61P1/00 , A61K31/675 , A61K31/4545 , A61K31/444 , A61K31/5377 , A61K31/685 , A61K2039/505
摘要： A prescription capable of avoiding induction of inflammatory cytokine production caused by a STING agonistic compound in a cancer patient, when suppressing the progression of, suppressing the recurrence of and/or treating cancer by the STING agonistic compound, is provided. A prescription that a STING agonistic compound is administered in combination with an adrenal corticosteroid when suppressing the progression of, suppressing the recurrence of and/or treating cancer. Methods for avoiding an induction of inflammatory cytokine production by administering the prescription in combination with an adrenal corticosteroid when administering a STING agonistic compound at reduced dosage in combination with an anti-neoplastic agent.
-
公开(公告)号：US11471436B2
公开(公告)日：2022-10-18
申请号：US15532389
申请日：2015-12-03
发明人： Kensuke Kusumi , Haruto Kurata , Atsushi Naganawa , Yasuyo Kodera , Yuichi Inagaki , Hiroya Takizawa , Mark Allan Wolf , Joseph Raker
IPC分类号： A61K31/397 , A61P25/28 , C07D205/04 , C07D401/10 , C07D207/16 , C07D403/10 , A61K31/015 , A61K31/19 , C07C13/20 , C07C13/48
摘要： A compound represented by general formula (I) wherein all the symbols are as defined in the specification has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e. g., neurodegenerative disease such as schizophrenia.
-
公开(公告)号：US20220204468A1
公开(公告)日：2022-06-30
申请号：US17695796
申请日：2022-03-15
IPC分类号： C07D309/06 , A61P25/20 , C07C233/81 , C07C235/64 , C07C327/48
摘要： An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
-
公开(公告)号：US11261154B2
公开(公告)日：2022-03-01
申请号：US17264603
申请日：2019-07-30
发明人： Shoji Nojima , Kenji Sasaki , Tohru Kambe , Takashi Konemura , Yoshikazu Goto
IPC分类号： C07C311/21
摘要： A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
-
公开(公告)号：US20220033371A1
公开(公告)日：2022-02-03
申请号：US17276284
申请日：2019-09-19
IPC分类号： C07D309/06 , C07C235/64 , C07C233/81 , C07C327/48 , A61P25/20
摘要： An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
-
-
-
-
-
-
-
-
-
搜索结果
886 条记录 (耗时 0.029 秒)
